Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk

被引：11
|
作者：
Arnott, Clare [1 ,2 ,3 ]
Fletcher, Robert A. [1 ]
Neal, Bruce [1 ,4 ]
机构：
[1] Univ New South Wales, George Inst Global Hlth, Level 5,1 King St, Sydney, NSW 2042, Australia
[2] Royal Prince Alfred Hosp, Dept Cardiol, Sydney, NSW, Australia
[3] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[4] Imperial Coll London, Dept Epidemiol & Biostat, London, England
来源：
HEART FAILURE CLINICS | 2022年 / 18卷 / 04期
关键词：
SGLT2; inhibitors; Meta-analysis; Amputation; Fracture; TYPE-2; CANAGLIFLOZIN;
D O I：
10.1016/j.hfc.2022.03.008
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：645 / 654
页数：10
相关论文
共 50 条
  • [41] The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern?
    Sarafidis, Pantelis A.
    Ortiz, Alberto
    CLINICAL KIDNEY JOURNAL, 2020, 13 (01) : 24 - 26
  • [42] Sodium-glucose cotransporter 2 inhibitors in real-life patients at high cardiovascular risk
    Cesaro, Arturo
    Fimiani, Fabio
    Gragnano, Felice
    Moscarella, Elisabetta
    Signore, Giovanni
    Maratea, Anna Chiara
    Rotolo, Francesco Paolo
    Vergara, Andrea
    Schiavo, Alessandra
    Calabro, Paolo
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (SUPPL G)
  • [43] Sodium-glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis
    Hamblin, Peter S.
    Wong, Rosemary
    Bach, Leon A.
    MEDICAL JOURNAL OF AUSTRALIA, 2021, 214 (02)
  • [44] Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis A Multicenter Cohort Study
    Douros, Antonios
    Lix, Lisa M.
    Fralick, Michael
    Dell'Aniello, Sophie
    Shah, Baiju R.
    Ronksley, Paul E.
    Tremblay, Eric
    Hu, Nianping
    Alessi-Severini, Silvia
    Fisher, Anat
    Bugden, Shawn C.
    Ernst, Pierre
    Filion, Kristian B.
    ANNALS OF INTERNAL MEDICINE, 2020, 173 (06) : 417 - +
  • [45] Lowering the risk of gout: Another benefits from the use of sodium-glucose cotransporter 2 inhibitors
    Sheu, Wayne H-H
    JOURNAL OF DIABETES INVESTIGATION, 2020, 11 (05) : 1115 - 1116
  • [46] Sodium-glucose cotransporter 2 inhibitors in real-life patients at high cardiovascular risk
    Cesaro, Arturo
    Fimiani, Fabio
    Gragnano, Felice
    Moscarella, Elisabetta
    Signore, Giovanni
    Maratea, Anna Chiara
    Rotolo, Francesco Paolo
    Vergara, Andrea
    Schiavo, Alessandra
    Calabro, Paolo
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0G)
  • [47] Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Bladder and Renal Cancer: Scandinavian Cohort Study
    Ueda, Peter
    Svanstrom, Henrik
    Hviid, Anders
    Eliasson, Bjorn
    Svensson, Ann-Marie
    Frazen, Stefan
    Gudbjornsdottir, Soffia
    Hveem, Kristian
    Jonasson, Christian
    Wintzell, Viktor
    Melbye, Mads
    Pasternak, Bjorn
    DIABETES CARE, 2022, 45 (05) : E93 - E96
  • [48] Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management
    Katsiki, Niki
    Mikhailidis, Dimitri P.
    Theodorakis, Michael J.
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (10) : 1522 - 1532
  • [49] Sodium-Glucose Cotransporter 2 Inhibitors and Lower-Extremity Amputation: Is the Guilty Verdict Valid?
    Pan, Meng
    Sturmer, Til
    DIABETES CARE, 2025, 48 (03) : 338 - 340
  • [50] Use of sodium-glucose co-transporter-2-inhibitors and risk of lower limb amputation
    Werkman, Nikki
    Nielen, Yannick
    van den Berg, Joop
    Ejskjaer, Niels
    Roikjer, Johan
    Schaper, Nicolaas
    Klungel, Olaf
    Vestergaard, Peter
    de Vries, Frank
    Driessen, Annemariek
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 593 - 594
12345